Radiopharmaceutical Clinical Trials in 2026: How to De-Risk Isotope Supply, Imaging Variability, and Regulatory Pathways

Radiopharmaceutical clinical trials evaluate drugs containing radioactive isotopes (radiopharmaceuticals) used for diagnostic imaging or targeted cancer therapy. They carry unique operational constraints: short isotope half-lives, multi-agency regulatory oversight from both drug and radiation safety authorities, dosimetry requirements, and a limited pool of licensed trial sites. In 2026, radiopharmaceutical development is moving from a promising niche into a high-velocity clinical reality. PET and SPECT are now embedded across diagnostic radiotracers, theranostics, and targeted radiotherapy programs, while pipelines expand in oncology, neurology, and cardiology. Yet the operational truth remains stubbornly specific.

Radiopharmaceutical trials do not fail for exotic reasons. They stall for predictable ones.

Axcellant’s execution data increasingly reflects this shift. As a boutique global CRO, Axcellant supports radiopharmaceutical and imaging-driven clinical programs across Europe and the United States through an integrated Imaging Core Lab model.

Why Radiopharmaceutical Trials Fail: Three Predictable Bottlenecks

Across recent PET and SPECT programs, three domains consistently dominate performance and timelines. These are isotope supply chain fragility, imaging variability, and (interdisciplinary teams cooperation). Each is manageable in isolation, but in practice, they interact and compound. The sponsors who consistently hit First Patient In (FPI) and maintain execution pace treat these variables as an integrated system from day one.

Key takeaways for sponsors in 2026 are increasingly clear. Programs that align isotope sourcing, imaging governance, and regulatory strategy early are materially more likely to protect timelines and preserve options. Programs that treat these domains as sequential workstreams tend to discover critical dependencies too late, when change is expensive, and delays become difficult to contain.

As Wojciech Kula, CEO of Axcellant, notes: „Radiopharmaceutical trials are operationally unforgiving. The sponsors who stay on schedule are those who integrate supply chain, imaging governance, and regulatory services execution into one coordinated system, early enough to preserve options and avoid downstream rework”.

In January 2026, Axcellant published a case study describing the on-time start of a multicenter diagnostic radiopharmaceutical trial despite single-source isotope supply constraints and incomplete CMO technology transfer. The conclusions mirror a broader pattern now visible across radiopharma. Execution success increasingly depends on integrated oversight that synchronizes supply, imaging operations, and quality governance in real time.

Isotope Supply Chain: A Protocol Risk, Not a Procurement Problem

Radioisotopes in Medicine are not conventional inputs. Their short half-lives and handling constraints mean they cannot be stockpiled. A trial can be scientifically ready and still be operationally blocked if the isotope supply is single-sourced, manufacturing capacity is narrow, or transport windows are insufficiently engineered.

What makes this risk newly visible at scale is the reality of multicenter execution. Sponsors often discover too late that a single qualified supplier creates multiple dependencies. Production scheduling, batch release timing, transport lane reliability, local receiving capability, and site readiness to dose precisely upon arrival of the product all become critical. In these programs, timelines are not governed by calendar planning but by minute-level synchronization.

A Parallel Execution Model for Supply De-Risking

A robust de-risking approach typically includes:

1. Mapping the full dependency chain, including supplier capacity, release cadence, transport lanes, receiving sites, and local radiation procedures.
2. Parallelizing CMO technology transfer with initial supply stabilization, rather than waiting for transfer completion before activation.
3. Designing enrollment around supply reality, not the other way around, to prevent waste, shortages, and rebooking cycles.

A multicenter diagnostic radiopharmaceutical program described by Axcellant illustrates the point. The sponsor faced a single-source isotope supply and incomplete CMO (the external facility responsible for producing the radiopharmaceutical drug product) technology transfer under tight, milestone-linked timelines. The solution was not to find another vendor overnight. It was a parallel execution model. Stabilize emergency supply from the source while accelerating tech transfer to additional manufacturing capacity, all under Class 7-compliant logistics planning. The reported outcome was on-time FPI and continued execution without pace collapse.

The core lesson is uncomfortable but useful. In radiopharma, the supply chain is part of clinical design. If it is treated as a downstream operation, it becomes an upstream delay.

Imaging variability is the silent driver of data risk

If supply chain fragility delays programs visibly, imaging variability undermines them quietly. Radiopharmaceutical trials frequently involve multiple PET, MRI or SPECT sites with different types of scanners, reconstruction settings, acquisition protocols, and local interpretation habits. Without central governance, variability accumulates invisibly and can erode statistical power, trigger protocol deviations, and compromise comparability across sites.

Hybrid imaging modalities such as PET/CT, SPECT/CT, and PET/MRI add further complexity, but also opportunity. When standardized well, hybrid imaging can reduce patient burden and compress timelines by combining procedures. When standardized poorly, it multiplies confounders.

Operationally Mature Imaging Governance

Operationally mature imaging strategies tend to include:

1. Protocol standardization across all sites, including acquisition parameters and reconstruction requirements.
2. Centralized imaging QA with defined acceptance thresholds and rapid feedback loops.
3. Blinded central reads to control interpretive variability and protect endpoint integrity.
4. KOL-level oversight where imaging endpoints materially affect go or no-go decisions.

This is why many sponsors are shifting toward an integrated CRO plus imaging core lab model, where imaging science, operational execution, and quality systems are coordinated rather than vendor siloed. It reduces handoff risk and shortens the time between image acquisition and analysis. In practice, it also reduces the number of late-cycle surprises that force protocol amendments, retraining waves, or data exclusions.

Regulatory pathway selection. Small misclassifications create large delays

Operational rigor cannot compensate for a misaligned regulatory path. Radiopharmaceutical studies sit at the intersection of pharmaceutical development, medical imaging, radiation protection, and country-specific licensing requirements. In both the EU and the US, the regulatory landscape is navigable, but it is rarely forgiving of assumptions.

RDRC vs. IND: When a Diagnostic Study Crosses the Threshold

In the US, sponsors sometimes explore the Radioactive Drug Research Committee (RDRC) route, a pathway that allows certain diagnostic radioactive drug studies to proceed without a full IND, provided the study does not evaluate efficacy or exceed defined radiation exposure limits.    

A diagnostic tracer study can cross regulatory thresholds when it includes components such as efficacy evaluation, biodistribution, bioavailability, or dosimetry. When that line is crossed, a full Investigational New Drug (IND) application to the FDA may be required (a substantially more resource-intensive submission that includes preclinical safety data, manufacturing information, and a detailed clinical protocol). Choosing incorrectly can lead to avoidable rejections, rework, and schedule delays.

A case example described by Axcellant underscores a practical best practice. When pathway applicability is ambiguous, engage in early consultation with regulators rather than betting the program on an interpretation that may not hold. In that instance, the RDRC pathway was deemed unsuitable. Still, an abbreviated preclinical package was deemed acceptable for IND submission, preventing a delay scenario caused by selecting the wrong procedural course at the outset.

The takeaway is not always taking the longer path. The takeaway is this. Select the path that matches the endpoints you are truly pursuing and validate assumptions early.

A Practical Execution Framework for 2026

Across programs, a consistent pattern emerges. Successful radiopharmaceutical trials are built on integration and tempo. The most resilient execution framework typically includes: 

1. Early integrated risk assessment spans isotope supply, imaging variability, regulatory pathway, and site capability.
2. Parallelization of manufacturing readiness, including CMO technology transfer, with trial start-up and imaging governance.
3. Centralized quality systems for imaging QA and blinded reads to reduce variability and rework.
4. Class 7 compliant logistics design engineered around half-life constraints and site-level dosing workflows.
5. Senior-led oversight with rapid escalation paths and real-time operational visibility.

 Axcellant operates under an Integrated CRO plus Imaging Core Lab model, which consolidates clinical operations, imaging science, and quality oversight into a single execution framework. In PET, MRI and SPECT trials, this shortens the decision path by consolidating imaging protocol standardization, site readiness, and issue escalation into a single accountable team, reducing vendor handoffs and eliminating delays caused by fragmented governance.

Radiopharmaceutical programs are scaling, but operational bottlenecks persist. Sponsors can materially improve the probability of meeting the timeline by adopting an execution-first clinical development posture